Explore FIGS stock price, latest earnings beat, technical analysis, valuation, and forecast. Is FIGS stock a buy? Get balanced insights for investors as of February 28, 2026.
Introduction
FIGS stock has drawn investor attention after a strong Q4 earnings beat. FIGS Inc. designs and sells medical apparel like scrubs for healthcare workers through an online platform. Broader market conditions favor consumer stocks amid economic recovery, but competition in apparel weighs on sentiment.
Latest Stock Price & Trend
FIGS stock closed at $15.27 on February 27, 2026, after surging 18.1% that day on earnings news. The 1-day gain reflects excitement from Q4 results. Over five days, shares rose sharply from recent lows around $13.
In the past month, FIGS stock climbed about 20%, building momentum. Three-month performance shows a 35% increase, while six months mark a 50% rise from lows. Year-to-date in 2026, it’s up over 90%.
The 52-week range spans $3.57 low to $15.63 high. This bullish trend signals growing confidence, but investors should watch for pullbacks near highs.
Technical Analysis
Support levels sit near $13.61, a recent low where buyers stepped in. Resistance looms at $15.63, the 52-week peak. Breaking it could spark more gains.
RSI reads around 65, neutral—not overbought yet, leaving room for upside. MACD shows bullish momentum with the line above the signal.
The 50-day moving average crossed above the 200-day, forming a golden cross for long-term bulls. Volume spiked on earnings, confirming the rally’s strength.
Analyst Ratings & Price Targets
Analysts rate FIGS stock mostly Hold, with 5 Buy, 14 Hold, and 1 Sell from recent coverage. Average price target is $9.88, ranging from $4.50 low to $17 high.
KeyBanc upgraded to Overweight at $17 on February 27, 2026, citing earnings strength. BTIG and Telsey also raised targets post-Q4. This mixed sentiment suggests caution despite upside potential.
Insider Activity
Insider selling dominates recent activity. Heather Hasson, Executive Chair, sold 22,874 shares on February 5, 2026, at around $4-5 per share earlier patterns show.
No major buying noted lately. Ongoing sales by executives imply caution, though routine for liquidity. Watch for shifts signaling confidence.
Valuation Analysis
Trailing P/E stands high at 125-180 due to low TTM EPS of $0.04-$0.11. Forward P/E could improve with growth. Price-to-sales is about 2.5x on $570M TTM revenue.
Revenue grew 1.8% YoY to $556M in 2024, but Q4 2025 jumped 33%. EPS improved sharply. FIGS holds strong cash, low debt.
Compared to peers like GIII (P/E 6.77), FIGS looks overvalued. Yet earnings momentum may justify premium—fairly valued at best.
Recent Earnings & Catalysts
Q4 2025 revenue hit $201.9M, up 33% YoY, beating estimates by 22%. EPS reached $0.10 vs. $0.02 expected, net income $18.5M.
Guidance points to continued growth via international expansion. Catalysts include margin gains to 13.2% EBITDA and cost controls. Stock jumped 18% post-earnings.
Bullish Case
Revenue catalysts stem from healthcare demand and international push. Technology like direct-to-consumer model boosts margins. Operational fixes lifted profitability.
Q4 beat shows demand resilience. Brand loyalty in scrubs aids steady growth without hype.
Bearish Case
U.S. sales weakness persists amid competition. High valuation risks pullback if growth slows. Margin pressures from costs linger.
Regulatory shifts in healthcare or economic dips could hit spending. Customer acquisition challenges noted.
Market Sentiment & Investor Psychology
Short interest ratio is 4.0, moderate bearishness. Institutional ownership steady, retail piled in post-earnings.
Options show call buying on surge. Sentiment tilts optimistic after Q4, but valuation caps enthusiasm—neutral overall.
Short-Term Outlook
Technicals favor upside with bullish MACD and volume. Momentum from earnings could push toward $17 resistance. Volatility high—expect consolidation.
Medium to Long-Term Outlook
FIGS’ model thrives on niche demand, but competition erodes moat. Financial health solid with cash flow gains. Long-term investors should hold or watch; accumulate on dips if growth sustains.
FAQ Section
Is FIGS stock a buy right now? Hold for now—strong earnings but high valuation and insider sales warrant caution.
What is the price target for FIGS stock? Average $9.88-$13.67, high $17 from KeyBanc.
What are major risks for FIGS stock? Slowing U.S. growth, competition, overvaluation.
FIGS stock forecast? Mixed; potential upside if margins hold.
What is FIGS earnings outlook? Positive post-Q4 beat, focus on international.
Internal Linking Suggestions
- Compare with Opendoor
- See our healthcare apparel sector breakdown
- Read scrubs market valuation trends
Final Balanced Conclusion
Hold. Earnings momentum supports stability, but valuation stretch and insider selling suggest waiting for better entry. Watch Q1 results.
Disclaimer: This article is for informational purposes only and not financial advice.